Small Molecule Inhibitors of Protein Kinase D: Early Development, Current Approaches, and Future Directions
Journal of Medicinal Chemistry · 12.01.2023 · 66 (1) · 122-139
DOI: 10.1021/acs.jmedchem.2c01599 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 20.12.2022. Verfasst von Qiming Jane Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States. Hauptthemen laut MEDLINE: Protein Kinase C, Protein Kinase Inhibitors. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, American Heart Association.
Abstract (Originalsprache)
Now entering its fourth decade, research on the biological function, small molecule inhibition, and disease relevance of the three known isoforms of protein kinase D, PKD1, PKD2, and PKD3, has entered a mature development stage. This mini-perspective focuses on the medicinal chemistry that provided a structurally diverse set of mainly active site inhibitors, which, for a brief time period, moved through preclinical development stages but have yet to be tested in clinical trials. In particular, between 2006 and 2012, a rapid expansion of synthetic efforts led to several moderately to highly PKD-selective chemotypes but did not yet achieve PKD subtype selectivity or resolve general toxicity and pharmacokinetic challenges. In addition to cancer, other unresolved medical needs in cardiovascular, inflammatory, and metabolic diseases would, however, benefit from a renewed focus on potent and selective PKD modulators.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, United States.
- Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania 15260, United States.
- School of Pharmacy, University of Eastern Finland, 70210 Kuopio, Finland.
ORCID-Profile: Peter Wipf
Förderung
- NCI NIH HHS
- National Cancer Institute
- American Heart Association
- Academy of Finland
Zitieren
APA
Wang, Q. J., & Wipf, P. (2023). Small Molecule Inhibitors of Protein Kinase D: Early Development, Current Approaches, and Future Directions. Journal of Medicinal Chemistry, 66(1), 122-139. https://doi.org/10.1021/acs.jmedchem.2c01599
Vancouver
Wang QJ, Wipf P. Small Molecule Inhibitors of Protein Kinase D: Early Development, Current Approaches, and Future Directions. Journal of Medicinal Chemistry. 2023;66(1):122-139. doi:10.1021/acs.jmedchem.2c01599
BibTeX
@article{Wang2023,
author = {Wang, Qiming Jane and Wipf, Peter},
title = {Small Molecule Inhibitors of Protein Kinase D: Early Development, Current Approaches, and Future Directions},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {1},
pages = {122--139},
doi = {10.1021/acs.jmedchem.2c01599}
}
EUVIMED